ALK and non-small cell lung carcinoma: NSCLC represents the leading cause of cancer death throughout the developed world, but the introduction of a novel class of targeted anti-neoplastic agents, EGFR and ALK TKI directed against EGFR and ALK, has significantly changed the therapeutic options available for patients with NSCLC.